• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Triazines Triazinethiones

Introduction to 1,3,5-Triazine-2(1H)-thione, 6-amino-4-(3-thienyl)- (CAS No: 1549588-02-4)

1,3,5-Triazine-2(1H)-thione, 6-amino-4-(3-thienyl)-, identified by its CAS number 1549588-02-4, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the triazine class of molecules, which are known for their versatile structural framework and broad spectrum of biological activities. The presence of both amino and thione functional groups in its molecular structure imparts unique reactivity and potential applications in drug discovery and synthesis.

The structural motif of 1,3,5-Triazine-2(1H)-thione, 6-amino-4-(3-thienyl)- features a central triazine ring substituted at the 6-position with an amino group and at the 4-position with a thiophene ring. This configuration creates a molecule with potential for multiple interactions with biological targets, making it a promising candidate for further investigation in medicinal chemistry. The thiophene moiety, in particular, is known to enhance the lipophilicity and metabolic stability of molecules, which are critical factors in drug design.

In recent years, there has been a growing interest in developing novel heterocyclic compounds for therapeutic applications. 1,3,5-Triazine-2(1H)-thione, 6-amino-4-(3-thienyl)- has been studied for its potential role in modulating various biological pathways. One of the most compelling areas of research involves its application in anticancer therapy. The triazine core is a well-documented scaffold in oncology research, with several derivatives already exhibiting significant cytotoxic effects against tumor cells. The addition of a thiophene group to this scaffold may enhance its binding affinity to specific cancer-related proteins and enzymes.

Moreover, the thione group in 1,3,5-Triazine-2(1H)-thione, 6-amino-4-(3-thienyl)- can participate in redox reactions, which is a key mechanism in many pharmacological interventions. This property allows the compound to potentially induce apoptosis or inhibit proliferation in cancer cells by disrupting their redox balance. Preliminary studies have suggested that this compound may also exhibit anti-inflammatory properties by interacting with inflammatory cytokine pathways. These findings are particularly intriguing given the high prevalence of chronic inflammatory diseases worldwide.

The synthesis of 1,3,5-Triazine-2(1H)-thione, 6-amino-4-(3-thienyl)- involves multi-step organic reactions that require careful optimization to ensure high yield and purity. The introduction of the amino group at the 6-position and the thiophene ring at the 4-position necessitates precise control over reaction conditions to avoid unwanted side products. Advances in synthetic methodologies have enabled more efficient production processes for such complex molecules, making them more accessible for further research and development.

In vitro studies have begun to uncover the mechanistic details of how 1,3,5-Triazine-2(1H)-thione, 6-amino-4-(3-thienyl)- exerts its biological effects. Initial experiments have shown that it can inhibit the activity of certain kinases involved in cell signaling pathways critical for cancer progression. Additionally, its ability to cross cell membranes suggests potential for topical applications as well as systemic therapy. These properties make it an attractive candidate for further exploration in drug development pipelines.

The role of computational chemistry has been instrumental in understanding the interactions between 1,3,5-Triazine-2(1H)-thione, 6-amino-4-(3-thienyl)- and biological targets. Molecular docking simulations have helped researchers predict binding affinities and identify potential binding sites on proteins relevant to cancer and inflammation. These computational approaches complement experimental efforts by providing rapid screening tools to evaluate multiple derivatives of this compound.

Recent advancements in biotechnology have also opened new avenues for exploring the therapeutic potential of 1,3,5-Triazine-2(1H)-thione, 6-amino-4-(3-thienyl)-. Gene editing technologies combined with small molecule inhibitors like this one offer a dual-pronged approach to treating complex diseases such as cancer. By targeting specific genetic mutations alongside molecular pathways modulated by small molecules like 1, researchers hope to develop more effective and personalized therapies.

The environmental impact of developing new pharmaceuticals is another critical consideration. While 1, shows promise as a therapeutic agent, sustainable synthesis methods are essential to minimize ecological footprints. Green chemistry principles are being increasingly applied to optimize synthetic routes for compounds like this one, ensuring that production processes are environmentally friendly without compromising efficacy.

Future directions for research on 1, include exploring its potential as an adjuvant therapy alongside existing treatments for cancer and inflammatory diseases. Combination therapies often yield better outcomes than single-agent treatments due to their ability to target multiple aspects of disease pathology simultaneously. Clinical trials are needed to validate these preclinical findings and assess the safety and efficacy of this compound in human populations.

In conclusion, has emerged as a promising candidate for further investigation in pharmaceutical research due to its unique structural features and potential biological activities.* Its central triazine core combined with functional groups such as amino*and thiophene*make it*an ideal scaffold*for developing novel therapeutics.*With ongoing studies*and advancements*in synthetic chemistry,*it is anticipated that *will contribute significantly*to addressing some*of today's most challenging medical conditions.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)